Coadministration with drugs that are inducers
of CYP450 3A4 may decrease the plasma concentrations and efficacy
of buprenorphine, which is metabolized in the liver by the isoenzyme. In addition, some of these inducers (anticonvulsants and barbiturates) may have additive central nervous system-depressant effects with buprenorphine.